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g.2013.0Abstract Objective: To use chorionic villi sampling (CVS) and amniocentesis to determine the
genotyping of Gaucher Disease (GD) of fetuses of pregnant mothers who had a previous child
affected by GD.
Methods: The study was conducted between January 2009 and December 2012. It included 42
pregnant women that gave informed written consent. Thirty mothers presented early so they under-
went CVS at 10–12 weeks of pregnancy while 12 mothers presented later and underwent amniocen-
tesis at 14–16 weeks. Strip assay for the identiﬁcation of Glucocerebrosidase (GBA) gene mutations
in the samples of chrorionic villi and amniotic ﬂuid was based on polymerase chain reaction (PCR)
and reverse hybridization.
Results: The age of the studied pregnant women ranged from 19 to 26 years. Consanguinity was
present in 38 cases. Eighteen women were pregnant in affected fetuses. The results of genotyping
revealed 15 cases were homozygous L444P/L444P and one case homozygous (N370s/N370s) while
two cases were heterogeneous (L444P/D409H). Twenty-four pregnant women had carrier fetuses
which were all heterozygous L444P.
Conclusion: This study highlights the ﬁndings of an extended gene mutation examination for
prenatal diagnosis of Guacher Disease. The study found out that the most common mutation
was L444P/L444P.
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6.0021. Introduction
Gaucher disease (GD) is a rare disease but is the commonest
enzyme deﬁciency disorder among the group of inherited lyso-
somal storage diseases [1]. It is caused by a deﬁciency in gluco-
cerebrosidase, a lysosomal hydrolase involved in the stepwise
degradation of complex glycosphingolipids, or in rare cases,in Shams University.
362 S. Elgawhary et al.by a deﬁciency in the activator protein saposin C [2]. GD is
classiﬁed based on clinical characteristics into three types:
Type 1 is a chronic non neuropathic form involving viscera
and blood forming tissues especially in Jewish population.
Type II is the infantile neuropathic form which always appears
by 6 months of age; it is rarer than type I and does not have
predominance in Jewish population, most patients die before
2 years of life. Type III is the chronic neuropathic form which
includes a heterogeneous group of patients with signs of slowly
progressive neurological disease that begins during childhood
or adolescence [3].
The diagnosis of GD is based on the assay of glucocerebro-
sidase activity in peripheral blood leucocytes or cultured ﬁbro-
blast that is signiﬁcantly lower than normal (<30%) [4]. More
than 300 mutant alleles have been identiﬁed. The presence of at
least one N370s allele is associated with Type 1 disease and
usually excludes neuropathic involvement [5] while individuals
who were homozygous for the L444P mutation tend to have
severe disease, with neurological complications. This mutation
results in an unstable enzyme with little or no residual activity.
In a study of 31 individuals with neurological complications,
L444P accounted for 25 alleles (40%) [6]. Mutation analysis is
the method of choice for the identiﬁcation of Gaucher disease
carriers. Carrier detection via enzymatic assay is unreliable be-
cause approximately 20% of obligate carriers demonstrate nor-
mal Glucocerebrosidase activity (false negative) i.e. an
individual with normal enzyme activity but has one copy of
any Gaucher disease mutation is an unaffected carrier.
Prenatal diagnosis for GD is now available at many centers.
This allows parents to consider termination or prepare for en-
zyme replacement therapy for the coming baby hoping to
change the disease nature course. The identiﬁcation of carriers
can be done by enzyme assay and molecular studies [5]. Carrier
and prenatal testing for people with family history of GD
should be offered in conjunction with genetic counseling [7].
The aim of this work was to undertake prenatal genotyping
diagnosis of Gaucher Disease for Egyptian pregnant mothers
who have a child suffering from GD.2. Patients and methods
The registry of affected families was accessed through the
Hematology outpatient clinic of the New Children Hospital
(Cairo University) and Neuro-Pediatric Unit at Fayoum Uni-
versity. A GD Registry is now maintained by several Univer-
sity Hospitals in Egypt as part of an informal network of
GD researchers. The development of this registry aims to offer
to treat affected cases using imiglucerase enzyme replacement
in line with the guidelines of the International Gaucher Disease
registry. The enzyme replacement therapy is sponsored by the
Gaucher Initiative U.S. Expert Medical Committee (US-EMC)
in collaboration with Project HOPE (http://www.projectho-
pe.org/) in Egypt. Currently there are around 130 children
treated under the project and every year 12–15 new cases are
added to the registry. The Fayoum University Research Ethics
Committee which is a member of Egyptian Network Research
Ethics Committee (ENREC) was informed of this study.
The present study included 42 pregnant women with previ-
ous children of GD who were diagnosed by enzyme assay of
Beta glucosidase activity in peripheral leucocytes and genotype
by molecular diagnosis (PCR). Those women had previouslygiven birth to a child with GD and were currently pregnant
with a child at risk of having GD. Mothers had hopes of hav-
ing unaffected children, or their future children could escape
the disease as carriers. After detailed counseling, informed
written consent was received from all the studied couples in
Arabic. A detailed description of the procedure (amniocentesis
or chorionic villus sampling (CVS)) according to the gesta-
tional age at presentation, the time interval between the proce-
dure and the availability of the report, and risks (such as fetal
or maternal trauma, infection, vaginal bleeding, feto-maternal
hemorrhage, or abortion) were explained adequately for cou-
ples at risk. All pregnant women were subjected to complete
physical and systemic examination. Comprehensive family his-
tory including consanguinity, affected siblings and a similar
condition in the family was taken.
According to age at presentation, 30 mothers underwent
CVS at 10–12 weeks of pregnancy and 12 mothers went for
amniocentesis at 14–16 weeks. The participating obstetrician
performed detailed abdominal ultrasound of the uterus and
pregnancy. None of the cases examined showed uterine or fetal
abnormalities detected by ultrasound. The abdomen was
cleaned using chlorhexidine solution. No local anesthesia and
the freehand technique were used for both procedures. An
obstetrician and an assistant controlling the scanning trans-
ducer performed the procedure.
For the CVS a 22 gauge single needle was used and passed
through the placenta in order to aspirate chorionic tissue. The
aspirated chorionic tissue was examined under microscopy to
exclude maternal contamination. The aspirated tissue was then
transported in Ham F-10 media to the laboratory. For the
amniocentesis, a 22 gauge single needle was passed under
ultrasound to a large pocket of amniotic ﬂuid away from the
fetus. A syringe was used to aspirate ﬁrst 1 cc and after con-
ﬁrming there was no maternal blood contamination 15–20 cc
of amniotic ﬂuid was aspirated and sent for analysis. Samples
collected were clearly labeled with the women’s information
and sent for analysis. All women were shown the fetus and fe-
tal heart rate before and after the procedure. All women were
asked to report immediately pain, bleeding or any concern.
Women returned back after 5–7 days to perform another ultra-
sound scan follow up. Eight Rh negative women received the
Anti-D antibodies after the procedure.
Strip assay for the identiﬁcation of Glucocerebrosidase
(GBA) gene mutations in the samples of chrorionic villi, was
based on polymerase chain reaction (PCR) and reverse hybrid-
ization. The procedure included three steps: (1) DNA isolation,
(2) PCR ampliﬁcation using biotinylated primers, (3) hybrid-
ization of ampliﬁcation products to a test strip containing allele
– speciﬁc oligonucleotide probes immobilized sequences are
detected using streptavidin–alkaline phosphatase and color
substrates. The assay covers 8 common GBA mutations:
84GG[452 + G], IVS2 + 1[484G > A], N370S[1226A >G],
V394L[1297G > T], D409H[1342G > C], L444P[1448T >
C], R463C[1504C > T], R496H[1604G.A], as well as 2
recombinant alleles derived from crossover between the GBA
functional gene and pseudogene. (The Vienna Lab Gaucher
Disease Strip Assay @4–250 (20 tests/kit) 2007). The same
technique for the identiﬁcation of Glucocerebrosidase (GBA)
gene mutations was used for the amniotic ﬂuid sample in
amniocentesis which was performed when mothers arrived for
prenatal diagnosis at 14–16 weeks which was later than the time
for CVS.
Table 1 Frequency of cases and carriers among study group.
Cases/carriers Frequency/
percentage
Homozygous/
heterozygous
Cases (L444P/L444P) 15 Homozygous
Cases (L444P/D409H) 2 Heterozygous
Cases (N370s/N370s) 1 Homozygous
Carriers (L444P) 24 Heterozygous
Table 2 Gene mutations among the 18 affected fetuses.
Frequency Percentage (%)
N370s /N370s 1 5.6
L444P/D409H 2 11
L444P/L444P 15 83.4
Table 3 Allele frequency among the studied fetuses.
Allele Frequency Percentage (%)
L444P 41 97.6
N370s 1 2.4
D409H 2 4.8
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The mean age of the studied pregnant women was 23.6 years
and ranged from 19 to 26 years. Positive consanguinity was
present in 38 (90.5%) of the studied population, ﬁrst cousin
consanguinity in 30 (71.4%) of them and remote degree con-
sanguinity in 8 (19.1%). Negative consanguinity was present
in only 4 (9.5%) of the studied group. The median gestational
age when carrying out the procedure was 13.8 weeks (range
10–16 weeks). There were no fetal losses related to the prenatal
diagnostic procedure. However, mild bleeding was encoun-
tered in two patients during CVS for which they needed rest
and observation for few hours and the bleeding stopped
spontaneously.Figure 1 Strip showing het
Figure 2 Strip showingTwenty-four fetuses (57.1%) proved to be carrier (trait)
while 18 (42.9%) proved to be affected. Five women out of
18 who were pregnant in affected fetuses decided to terminate
their pregnancy, while the remaining women decided to con-
tinue the pregnancy according to their religious believes. Ba-
bies to mothers that underwent CVS or amniocentesis were
born without evidence of complications due to the procedure.
Genotype analysis of the studied individuals is shown in
Tables 1–3 as well as Figs. 1–3.
4. Discussion
Gaucher disease is the most prevalent lysosomal storage dis-
eases which results from inherited deﬁciency in the glucocere-
brosidase enzyme.
Previous molecular studies of the disease mutations re-
vealed that although more than 50 mutations were identiﬁed
in the glucocerebrosidase gene, only four of them frequently
occurred. These four common mutations are L444P,D409H,
N370s and IVS2 + 1, representing 90–95% of the mutations
GD in the Ashkenazi Jewish population, and 50–75% of muta-
tions in general population [8,9]. Recently, more than 200
mutations have been found in patients with GD, and certain
mutations have a higher frequency in certain populations. El
morsy and co-workers (2011) found that type II and III GD
patients had Rec alleles/L444P genotypes (100%) with a poor
phenotype/genotype correlation in Egyptian population [10].
In the current study the IVS2 + 1 mutation was not in-
volved in our molecular diagnosis, which is in agreement with
Koprivica and co-workers who reported that IVS2 + 1 muta-
tion accounted for 1% only in non Ashkenazi Jewish [6]. Tsujii
in 1987 [11] reported that L444P mutation occurs more fre-
quently in non Jewish population, moreover, El-Beshlawy with
her colleagues in 2006 [12] found that 14 of 22 patients (63.6%)
were accounting for L444p mutation as homozygous or het-
erozygous with D409H mutations. In the study by Khalifa
and co-workers in 2011, molecular analysis was performed
over 23 patients, and the commonest genotype was homozy-
gous L444P which was present in 13 patients (56.5%) in
their study followed by homozygous N370S; found in three
patients (13.04%) [13]. The percentage of occurrence oferozygote hybridization.
N370/N370 mutation.
Figure 3 Strip showing a double heterozygote L444P/D409H mutation.
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homozygous or compound heterozygous with D409H muta-
tions and N370s /N370s (homozygous) was found in only
one patient (5.6%).
Since most of Egyptian children with Gaucher disease have
type III disease and L444P/L444P genotype, a minimum dose
of recombinant enzyme imiglucerase (cerezyme) 60 U/kg/
2 weeks should be maintained until adulthood and higher
doses started at an early age may delay the progression of neu-
rological symptoms [13]. These previous results drove our
attention to the importance of what we found as the most com-
mon mutations encountered in the current study which were
L444p/L444p (homozygous) in 15 cases out of 18 affected fe-
tuses (83.4%), followed by L444P/D409H(double heterozy-
gous) in two cases (11%), whereas N370s /N370s
(homozygous) was found in only one (5.6%). This highlights
the importance of early enzyme replacement therapy for the
coming baby to improve the disease nature course and delay
the progression.
All cases with the genotypes L444p/L444p and N370S/
N370S were from consanguineous parents i.e. 15 cases of 15
and one case of 1 respectively. Although 24 cases were carrier
for GD with heterozygous L444p mutation, only four cases
had negative consanguinity. So this study conﬁrmed that
about 100% of our affected cases were from consanguineous
pedigree while 16.6% of carrier state was from non consan-
guineous marriage. These results exceeded what was reported
by El-Beshlawy with her colleagues in 2006 who found that
two thirds of their patients were from consanguineous mar-
riage [12], while El-Gawhary in 1999 revealed that 80% of
cases were from consanguineous parents and 30% with af-
fected sibilings [14]. In another study, of El-Gawhary and
co-authors stressed the signiﬁcance of premarital as well as
pre-natal counseling of the disease for families with affected
children [15]. New developments which will allow for preim-
plantation genetic diagnosis for those women that can afford
to undergo intra cytoplasmic sperm injection (ICSI) will allow
couples to avoid having children with GD and the need to un-
dergo prenatal testing.
5. Conclusions
The high frequency of positive consanguinity and the mode of
inheritance drive the attention to the importance of genetic
counseling and pre-natal diagnosis of the GD among high risk
cases in Egypt. The most common mutation found in our
study was L444p/L444p in the affected fetuses that may need
a higher dose of enzyme replacement starting at an early age
of life to delay the progression of possible neurological symp-
toms. The low acceptance rate to termination of pregnancyhighlighted the need for one of the earlier preventive
approaches such as preimplantation genetic diagnosis for those
women that can afford to undergo intra cytoplasmic sperm
injection (ICSI).
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